These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 30383218)
1. Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy. Colombo C; De Leo S; Di Stefano M; Vannucchi G; Persani L; Fugazzola L J Clin Endocrinol Metab; 2019 Mar; 104(3):779-784. PubMed ID: 30383218 [TBL] [Abstract][Full Text] [Related]
2. Cortisol Deficiency in Lenvatinib Treatment of Thyroid Cancer: An Underestimated Common Adverse Event. Monti S; Presciuttini F; Deiana MG; Motta C; Mori F; Renzelli V; Stigliano A; Toscano V; Pugliese G; Poggi M Thyroid; 2022 Jan; 32(1):46-53. PubMed ID: 34663079 [No Abstract] [Full Text] [Related]
3. Impact of systemic treatments for advanced thyroid cancer on the adrenal cortex. Colombo C; Ceruti D; Succi M; De Leo S; Trevisan M; Moneta C; Fugazzola L Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38642580 [TBL] [Abstract][Full Text] [Related]
4. Lenvatinib: Role in thyroid cancer and other solid tumors. Cabanillas ME; Habra MA Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514 [TBL] [Abstract][Full Text] [Related]
5. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399 [TBL] [Abstract][Full Text] [Related]
6. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up. Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. Hu MI; Elisei R; Dedecjus M; Popovtzer A; Druce M; Kapiteijn E; Pacini F; Locati L; Krajewska J; Weiss R; Gagel RF Endocr Relat Cancer; 2019 Feb; 26(2):241-250. PubMed ID: 30557850 [TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis. Oba T; Chino T; Soma A; Shimizu T; Ono M; Ito T; Kanai T; Maeno K; Ito KI Endocr J; 2020 Dec; 67(12):1215-1226. PubMed ID: 32814730 [TBL] [Abstract][Full Text] [Related]
10. Drug safety evaluation of lenvatinib for thyroid cancer. Krajewska J; Kukulska A; Jarzab B Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847 [TBL] [Abstract][Full Text] [Related]
11. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189 [TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489 [TBL] [Abstract][Full Text] [Related]
13. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. Brose MS; Panaseykin Y; Konda B; de la Fouchardiere C; Hughes BGM; Gianoukakis AG; Joo Park Y; Romanov I; Krzyzanowska MK; Leboulleux S; Binder TA; Dutcus C; Xie R; Taylor MH J Clin Endocrinol Metab; 2022 Feb; 107(3):776-787. PubMed ID: 34664662 [TBL] [Abstract][Full Text] [Related]
14. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914 [No Abstract] [Full Text] [Related]
15. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort. Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619 [TBL] [Abstract][Full Text] [Related]
17. Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives. Verburg FA; Amthauer H; Binse I; Brink I; Buck A; Darr A; Dierks C; Koch C; König U; Kreissl MC; Luster M; Reuter C; Scheidhauer K; Willenberg HS; Zielke A; Schott M Horm Metab Res; 2021 Mar; 53(3):149-160. PubMed ID: 33652491 [TBL] [Abstract][Full Text] [Related]
18. Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer. Giani C; Valerio L; Bongiovanni A; Durante C; Grani G; Ibrahim T; Mariotti S; Massa M; Pani F; Pellegriti G; Porcelli T; Salvatore D; Tavarelli M; Torlontano M; Locati L; Molinaro E; Elisei R Thyroid; 2021 Feb; 31(2):224-232. PubMed ID: 32907501 [No Abstract] [Full Text] [Related]
19. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442 [TBL] [Abstract][Full Text] [Related]
20. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]